Departments of Pediatrics and.
Discipline of Paediatrics, Adelaide Medical School and Robinson Research Institute, The University of Adelaide, Adelaide, Australia.
Pediatrics. 2018 Apr;141(4). doi: 10.1542/peds.2017-3742. Epub 2018 Mar 7.
Hormonal interventions are being increasingly used to treat young people with gender dysphoria, but their effects in this population have not been systematically reviewed before.
To review evidence for the physical, psychosocial, and cognitive effects of gonadotropin-releasing hormone analogs (GnRHa), gender-affirming hormones, antiandrogens, and progestins on transgender adolescents.
We searched Medline, Embase, and PubMed databases from January 1, 1946, to June 10, 2017.
We selected primary studies in which researchers examined the hormonal treatment of transgender adolescents and assessed their psychosocial, cognitive, and/or physical effects.
Two authors independently screened studies for inclusion and extracted data from eligible articles using a standardized recording form.
Thirteen studies met our inclusion criteria, in which researchers examined GnRHas ( = 9), estrogen ( = 3), testosterone ( = 5), antiandrogen (cyproterone acetate) ( = 1), and progestin (lynestrenol) ( = 1). Most treatments successfully achieved their intended physical effects, with GnRHas and cyproterone acetate suppressing sex hormones and estrogen or testosterone causing feminization or masculinization of secondary sex characteristics. GnRHa treatment was associated with improvement across multiple measures of psychological functioning but not gender dysphoria itself, whereas the psychosocial effects of gender-affirming hormones in transgender youth have not yet been adequately assessed.
There are few studies in this field and they have all been observational.
Low-quality evidence suggests that hormonal treatments for transgender adolescents can achieve their intended physical effects, but evidence regarding their psychosocial and cognitive impact are generally lacking. Future research to address these knowledge gaps and improve understanding of the long-term effects of these treatments is required.
激素干预措施被越来越多地用于治疗患有性别焦虑症的年轻人,但在此人群中,尚未对其效果进行系统评价。
综述促性腺激素释放激素类似物(GnRHa)、性别肯定激素、抗雄激素和孕激素对跨性别青少年的身体、心理社会和认知影响的证据。
我们检索了 Medline、Embase 和 PubMed 数据库,检索时间为 1946 年 1 月 1 日至 2017 年 6 月 10 日。
我们选择了研究人员检查跨性别青少年激素治疗并评估其心理社会、认知和/或身体影响的原始研究。
两名作者独立筛选研究纳入情况,并使用标准化记录表格从合格文章中提取数据。
13 项研究符合我们的纳入标准,研究人员检查了 GnRHa(n = 9)、雌激素(n = 3)、睾丸激素(n = 5)、抗雄激素(醋酸环丙孕酮)(n = 1)和孕激素(左炔诺孕酮)(n = 1)。大多数治疗方法成功地实现了其预期的身体效果,GnRHa 和醋酸环丙孕酮抑制性激素,而雌激素或睾丸激素导致第二性征的女性化或男性化。GnRHa 治疗与多种心理功能测量的改善相关,但与性别焦虑症本身无关,而性别肯定激素对跨性别青年的心理社会影响尚未得到充分评估。
该领域的研究较少,且均为观察性研究。
低质量证据表明,对跨性别青少年的激素治疗可以实现其预期的身体效果,但关于其心理社会和认知影响的证据通常缺乏。需要进一步研究来解决这些知识空白,并更好地了解这些治疗方法的长期影响。